In arsenic trioxide (1 μM) and ATRA (1 μM) synergistically play inhibitive effect on OCI-AML3 and primary AML cells harboring an NPM1 mutation, with little effect on non-APL wild type NPM1 AML cells. Here, NPM1 is linked to acute promyelocytic leukemia.